Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1601 - 1625 of 2860 in total
BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).
Investigational
Experimental
Matched Synonyms: … 9-Oxo-N-(2H-tetrazol-5-yl)-9H-xanthene-2-sulfonamide …
Matched Name: … N-(1,4-dihydro-5H-tetrazol-5-ylidene)-9-oxo-9H-xanthene-2-sulfonamide …
Matched Iupac: … N-(4,5-dihydro-1H-1,2,3,4-tetrazol-5-ylidene)-9-oxo-9H-xanthene-2-sulfonamide …
Experimental
Matched Name: … [(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid …
Matched Iupac: … 2-[(3S)-9-hydroxy-1-methyl-10-oxo-3H,4H,10H-naphtho[2,3-c]pyran-3-yl]acetic acid …
Investigational
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Investigational
Investigational
Investigational
Experimental
Investigational
IK-930 is an oral, paralog-selective TEAD inhibitor.
Investigational
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Iupac: … N-[6-(diethylamino)hexyl]-6-methoxy-4-methylquinolin-8-amine …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Investigational
Experimental
Matched Synonyms: … 9-phenanthrenamine ... 9-phenanthrylamine ... phenanthren-9-amine …
Matched Name: … 9-Aminophenanthrene …
Matched Iupac: … phenanthren-9-amine …
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
R-95845 is an inhibitor of HIV-1 reverse transcriptase.
Experimental
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Investigational
Matched Iupac: … 2-methylpropyl (2S)-2-{[({2-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy}methyl)({[(2S)-1-(2-methylpropoxy …
ILS-920 is under investigation in clinical trial NCT00827190 (Study Evaluating Single Ascending Doses Of ILS-920).
Investigational
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Investigational
Displaying drugs 1601 - 1625 of 2860 in total